<table>
<thead>
<tr>
<th>Title</th>
<th>The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Sato, Seiichi; Li, Kai; Kameyama, Takeshi; Hayashi, Takaya; Ishida, Yuji; Murakami, Shuko; Watanabe, Tsunamasa; Iijima, Sayuki; Sakurai, Yu; Watashi, Koichi; Tsutsumi, Susumu; Sato, Yusuke; Akita, Hidetaka; Wakita, Takaji; Rice, Charles M.; Harashima, Hideyoshi; Kohara, Michinori; Tanaka, Yasuhito; Takaoka, Akinori</td>
</tr>
<tr>
<td>Citation</td>
<td>Immunity, 42(1): 123-132</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2015-01-20</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/62620">http://hdl.handle.net/2115/62620</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license</td>
</tr>
<tr>
<td>Type</td>
<td>article (author version)</td>
</tr>
<tr>
<td>Note</td>
<td>Supplemental materials are available on the publisher's website.</td>
</tr>
<tr>
<td>File Information</td>
<td>Immunity42_123.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
The RNA Sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus

Seiichi Sato,1,2,10 Kai Li,1,2,10 Takeshi Kameyama,1,2,10 Takaya Hayashi,3,10 Yuji Ishida,4 Shuko Murakami,5 Tsunamasa Watanabe,5 Sayuki Iijima,5 Yu Sakurai,6 Koichi Watashi,7 Susumu Tsutsumi,5 Yusuke Sato,6 Hidetaka Akita,6 Takaji Wakita,7 Charles M. Rice,8 Hideyoshi Harashima,6 Michinori Kohara,9 Yasuhiro Tanaka,5 and Akinori Takaoka1,2,*

1Division of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
2Molecular Medical Biochemistry Unit, Biological Chemistry and Engineering Course, Graduate School of Chemical Sciences and Engineering, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
3Research Center for Infection-associated Cancer, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
4PhoenixBio Co., Ltd., Higashi Hiroshima, Hiroshima 739-0046, Japan
5Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan
6Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan
7Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan
8Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA
9Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo 156-8506, Japan
10These authors contributed equally to this work.
*Correspondence: takaoka@igm.hokudai.ac.jp

RUNNING TITLE: RIG-I functions as a dual effector against HBV
File length: 54,595 characters including figure legends and references
SUMMARY

Host innate recognition triggers key immune responses for viral elimination. The sensing mechanism of hepatitis B virus (HBV), a DNA virus, and the subsequent downstream signaling events remain to be fully clarified. Here we found that type III but not type I interferons are predominantly induced in human primary hepatocytes in response to HBV infection, through retinoic acid-inducible gene-I (RIG-I)-mediated sensing of the 5’-ε region of HBV pregenomic RNA. In addition, RIG-I could also counteract the interaction of HBV polymerase (P protein) with the 5’-ε region in an RNA-binding dependent manner, which consistently suppressed viral replication. Liposome-mediated delivery and vector-based expression of this ε region-derived RNA in liver abolished the HBV replication in human hepatocyte-chimeric mice. These findings identify an innate recognition mechanism by which RIG-I dually functions as an HBV sensor activating innate signaling and to counteract viral polymerase in human hepatocytes.

Received: June 23, 2014
Accepted: December 3, 2014
Published: December 31, 2014

INTRODUCTION

Hepatitis B virus (HBV) is a hepatotropic virus of the Hepadnaviridae family and contains a circular, partially double-stranded DNA genome of about 3.2-k base pairs that is replicated via reverse transcription of a pregenomic RNA (pgRNA). HBV causes hepatic inflammation associated with substantial morbidity worldwide (Rehermann and Nascimbeni, 2005; Protzer et al., 2012; Revill and Yuan, 2013). Around four hundred million people worldwide are persistently infected with HBV, which is a major causative factor associated with not only inflammation but also cirrhosis and even cancer of the liver. Currently, interferon and nucleoside/nucleotide analogues are available for HBV treatment
(Rehermann and Nascimbeni, 2005; Halegoua-De Marzio and Hann, 2014). However, the long-term response rates are still not satisfactory. Elucidation of host immune response against HBV infection is crucial for better understanding of the pathological processes and viral elimination to control HBV infection.

The type I interferons (IFNs), IFN-α and IFN-β, are representative cytokines that elicit host innate immune responses against viral infections. In addition, another IFN family, type III IFNs (IFN-λ, also known as IL-28 and IL-29) exhibits potent antiviral activity similar to IFN-α and -β (Sheppard et al., 2003; Kotenko, 2011; Kotenko et al., 2003). Production of type I and type III IFNs is massively induced in many types of cells upon infection with various viruses, which is known to be mediated by the activation of pattern recognition receptors (PRRs). During virus infection, virus-derived nucleic acids (both RNA and DNA) are mainly sensed by certain PRRs, such as retinoic acid-inducible gene-I (RIG-I) (Yoneyama et al., 2004; Choi et al., 2009; Chiu et al., 2009; Ablasser et al., 2009), melanoma differentiation-associated gene 5 (MDA5) (Yoneyama et al., 2005), cyclic GMP-AMP synthase (cGAS) (Sun et al., 2013), and gamma-interferon-inducible protein 16 (IFI16) (Unterholzner et al., 2010). Particularly, RIG-I is a key PRR that can detect virus-derived RNAs in the cytoplasm during infection with a variety of viruses, such as influenza virus, hepatitis C virus (HCV), and measles virus, which are closely related to human disease pathogenesis (Rehwinkel and Reis e Sousa, 2010). Binding of RIG-I to its ligand RNAs, such as 5’-triphosphorylated RNA or short double-stranded RNAs (Takeuchi and Akira, 2009; Hornung et al., 2006), activates the downstream signaling pathways in a manner dependent on the adaptor protein mitochondrial antiviral signaling protein (MAVS; also known as IPS-1, VISA or Cardif) (Takeuchi and Akira, 2009), leading to the induction of the interferon-regulatory factor-3 (IRF-3) and nuclear factor-κ B (NF-κB)-dependent gene expression and the subsequent production of type I and type III IFNs and inflammatory cytokines (Takeuchi and Akira, 2009). Thus, RIG-I sensing of viral RNA is a crucial process to activate the antiviral innate responses to limit viral replication and the activation of adaptive immunity (Takeuchi and Akira, 2009).

As for the viruses that are known to the leading cause of hepatic inflammation, RIG-I is the major PRR that initiates innate immune responses against HCV. RIG-I sensing of HCV
is mediated through its recognition of the poly-U/UC motif of the HCV RNA genome 3’ non-translated region, which leads to the activation of type I IFN response (Saito et al., 2008). On the other hand, earlier studies have shown that the innate immune activation is impaired and the induction of type I IFNs such as IFN-α or IFN-β is hardly detected in animal models of HBV infection, as compared with HCV infection (Wieland et al., 2004; Nakagawa et al., 2013). However, it is still not fully clarified how HBV is recognized by human hepatocytes and the role of type III IFNs as well.

Here we report that HBV infection predominately induces type III but not type I IFN gene induction, which is mediated by RIG-I through its recognition of the 5’-ε region of HBV-derived pgRNA. We also show that RIG-I can counteract the interaction of HBV polymerase (P protein) with the 5’-ε region of pgRNA in an RNA-binding dependent manner, resulting in the suppression of HBV replication. Furthermore, liposome-mediated delivery and expression of the 5’-ε region-derived RNA in liver suppressed the HBV replication in vivo in chimeric mice with humanized livers. Thus, our findings demonstrate the innate defense mechanisms based on the viral RNA-RIG-I interaction, whereby RIG-I functions not only as a HBV sensor for the activation of IFN response, but also as a direct antiviral factor.

RESULTS

Type III IFNs are predominantly induced in hepatocytes during HBV infection

To investigate the innate immune activation during HBV infection, we examined type I and type III IFN responses in human hepatocytes. Consistent with the previous reports (Wieland et al., 2004; Nakagawa et al., 2013), we hardly observed the induction of type I IFNs, IFN-α4 and IFN-β in response to transfection with plasmids carrying 1.24-fold the HBV genome of three major different genotypes, Ae (HBV-Ae), Bj (HBV-Bj), and C (HBV-C) (Figures 1A and S1A available online) at least up to seven days after transfection, although the expression of HBV RNAs was detectable (Figure S1B). On the other hand, type III IFN, IFN-λ1, was induced in all of the three types of human hepatocyte cell line tested (Figures 1A and S1A). In HepG2 cells, HBV-C shows the highest IFN-λ1 response, which was also
confirmed by ELISA albeit weakly (Figures 1A and 1B). Moreover, IFN-λ1 in culture supernatant could inhibit Vesicular stomatitis virus (VSV) replication in plaque reduction assay as well as HBV replication (Figure S1C), indicating the physiological relevance of the induced IFN-λ1 to antiviral activities. Consistent with these results, we observed the significant induction of not only IFN-λ1 but also IFN-λ2 and -λ3 in primary human hepatocytes (PHH) in vitro 24 hr after infection with HBV-C (Figure 1C); however, neither of type I nor type II IFN tested was induced (Figures S1D and S1E). Although it is difficult to simply compare the amount of IFN induced by different types of virus, the induction of IFN-λ1, λ2, and λ3 mRNAs in response to HBV infection was much weaker than that of Newcastle disease virus (NDV) infection (Figure 1C). In this regard, in order to rule out the possibility that the IFN-λ response is due to contaminants in the inocula, we used Lamivudine (LAM), an HBV inhibitor, in this assay. Treatment with LAM inhibited IFN-λ mRNA induction in response to HBV infection in PHH (Figure 1C), suggesting that the IFN response is actually induced by HBV replication. Furthermore, we analyzed HepG2-sodium taurocholate cotransporting polypeptide (NTCP)-C4 cell line (Iwamoto et al., 2014) stably expressing human NTCP, a functional receptor for HBV (Yan et al., 2012), and confirmed that IFN-λ1 and IFN-inducible genes such as OAS2 and RSAD2, but not IFN-β were induced in these cells after infection with HBV-C, and that these inductions were abolished by treatment with LAM (Figure 1D). To next assess the innate immune responses in vivo during HBV infection, we exploited severe combined immunodeficiency mice that carry the urokinase-type plasminogen activator transgene controlled by an albumin promoter (uPA+/−/SCID mice), in which more than 70% of murine hepatocytes were replaced by human hepatocytes (Tateno et al., 2004) (hereinafter referred to as chimeric mice). After the chimeric mice were intravenously infected with HBV-C, which was derived from patient with chronic hepatitis, the expression of type III IFN mRNAs increased in the liver tissue, whereas IFN-α4 and IFN-β mRNAs was not upregulated (Figure 1E). In parallel with this type III IFN response, we also observed the expression of IFN-inducible genes, such as CXCL10, OAS2, and RSAD2, in the human liver of these infected mice (Figure 1E). These findings indicate that a moderate type III but not type I or type II IFN response is activated in human hepatocytes in response to HBV infection.
HBV-induced type III IFN expression depends on RIG-I

We next determined which sensor-mediated signaling pathway is responsible for the HBV-induced type III IFN response. As HBV is a DNA virus (Rehermann and Nascimbeni, 2005; Protzer et al., 2012; Revill and Yuan, 2013), we assessed the contribution of previously reported cytosolic DNA sensors including RIG-I (Chiu et al., 2009; Ablasser et al., 2009; Choi et al., 2009), IFI16 (Unterholzner et al., 2010), and cGAS (Sun et al., 2013) in human hepatocytes. Knockdown analyses revealed that IFN-λ1 induction in HepG2 or Huh-7 cells by plasmid transfection for HBV-C or HBV-Ae, respectively, was suppressed by the knockdown of RIG-I but not that of the other sensors (Figures 2A, S2A and S2B). To further confirm the involvement of RIG-I in HBV-triggered type III IFN response, we measured IFN-λ1 mRNA expression induced by plasmid expression in Huh-7.5 cells that carry a dominant-negative mutant RIG-I allele that prevents RIG-I signaling (Saito et al., 2007), as compared with Huh-7 cells that have an intact RIG-I pathway. Huh-7.5 cells failed to induce IFN-λ1 mRNA expression in response to HBV-Ae genome plasmid transfection, as in the case of stimulation with 5’-triphosphate RNA (3pRNA), a RIG-I ligand (Takeuchi and Akira, 2009; Hornung et al., 2006) (Figure 2B). In concordance with this result, knockdown of tripartite motif containing protein 25 (TRIM25), MAVS, TANK-binding kinase 1 (TBK1), and IRF-3, all of which are signaling molecules essentially involved in the RIG-I-mediated IFN pathway (Takeuchi and Akira, 2009), resulted in the suppression of IFN-λ1 mRNA induction in HepG2 cells in response to transfection with the HBV-C genome. On the other hand, such an effect was not observed in cells treated with either TRIF (also known as TICAM-1) or MYD88 siRNA (Figures 2C and S2C). In addition, we confirmed that the knockdown of RIG-I and MAVS abolished IFN-λ1 induction in PHH infected with each genotype (Figure 2D). Furthermore, we also confirmed by knockdown assay that the induction of IFN-λ1 and OAS2 mRNA in HepG2-hNTCP-C4 cells in response to infection with HBV-C was dependent on RIG-I (Figure S2E). These data indicate that IFN-λ1 gene induction during HBV infection depends largely on RIG-I signaling pathway.
The 5’-ε region of HBV pgRNA is a key element for RIG-I-dependent IFN-λ1 induction

RIG-I can recognize not only virus-derived RNA but also DNA in the cytoplasm (Yoneyama et al., 2004; Choi et al., 2009; Chiu et al., 2009; Ablasser et al., 2009). To further clarify how RIG-I recognizes HBV, we first examined either or both of which nucleic acid (DNA and RNA) derived from HBV-infected cells can activate IFN-λ1 gene expression. Transfection with nucleic acid fractions extracted from HBV infected Huh-7 cells after pretreatment with RNase A but not DNase I resulted in marked inhibition of the IFNL1 promoter activation, suggesting that virus-derived RNAs may be candidates of the RIG-I ligand during HBV infection (Figure 3A).

The HBV genome comprises a partially double-stranded 3.2-kb DNA. During a life cycle of HBV in hepatocytes, its covalently closed circular DNA (cccDNA) is transcribed to generate four major RNA species: the 3.5-, 2.4-, 2.1- and 0.7-kb viral RNA transcripts (Rehermann and Nascimbeni, 2005; Protzer et al., 2012; Revilla and Yuan, 2013). We created an siRNA to suppress the expression of all of these RNA transcripts and tested its effect on HBV-induced IFN-λ1 expression. As shown in Figure 3B, knockdown with this siRNA (Figure S3A) suppressed IFN-λ1 induction in Huh-7 cells transfected with HBV-Ae. Next, to determine which of these HBV RNA transcripts is/are involved in the RIG-I-mediated IFN-λ1 induction, we prepared expression vectors to express each of these four viral transcripts in HEK293T cells that are often used to analyze RIG-I signaling pathway in human cells. As a result, it is only the longest 3.5-kb transcript, that is, pgRNA, that has the potential to elicit a significant induction of IFN-λ1 mRNA (Figures 3C and S3B). It was also confirmed by knockdown analysis with pgRNA-targeted siRNA, which showed significant suppression of IFN-λ1 induction in HepG2 cells transfected with HBV-Ae (Figure S3C). These results suggest that 5’-1.1-kb region of HBV pgRNA is critical for the activation of RIG-I pathway to induce IFN-λ1 expression. On the other hand, the remaining three transcripts, which also contain the same sequence of part of this 1.1-kb region of HBV pgRNA at the 3’ end of their transcripts, failed to induce IFN-λ1 mRNA (Figure 3C). An artificially deleted form of pgRNA, which lacks this overlapping sequence at the 3’-region (Δ3), showed IFN-λ1 induction, whereas such response was not observed
for another mutant pgRNA lacking it at the 5’-region (Δ5) (Figure 3D). These data also support a possible important role of the 5’-overlapping sequence of HBV pgRNA for RIG-I-mediated IFN-λ1 induction.

The 5’-end of HBV pgRNA is known to contain the encapsidation sequence, called “epsilon (ε)”, which takes a stem-loop secondary structure (Junker-Niepmann et al., 1990; Pollack and Ganem, 1993; Knaus and Nassal, 1993; Jeong et al., 2000). Therefore, we hypothesized that this 5’-ε structure may confer a possible pathogen-associated molecular pattern (PAMP) motif for RIG-I recognition. To test this hypothesis, we stimulated HEK293T and HepG2 cells with the ε-region-derived RNA (hereafter called εRNA). Consequently, IFN-λ1 mRNA was significantly induced, which was dependent on RIG-I while such response was not detected upon stimulation with the equivalent length of RNA that is derived from HBV pgRNA but does not contain any ε element (ContRNA) (Figures 3E and S3D). We also confirmed RIG-I-dependent IRF-3 activation in response to stimulation with εRNA (Figures S3D and S3E). Due to the overlapping sequence of 5’- and 3’-ends of HBV pgRNA as mentioned above, this ε element is found at both ends of pgRNA. We next generated several mutant forms of HBV pgRNA, each of which carries mutations within 5’- or 3’-ε region or both to disrupt the stem-loop structure (5STM, 3STM or 5&3STM, respectively). In concordance with the results shown in Figures 3C, 3D and S3B, IFN-λ1 mRNA induction was detected upon expression of the 3STM transcript that has an intact 5’-ε region, as similar to that of intact 3.5-kb pgRNA (Figure 3F). In contrast, either 5STM or 5&3STM did not show significant response. These findings indicate that the 5’-ε region of HBV pgRNA is critical for IFN-λ1 induction possibly through the recognition by RIG-I.

**RIG-I interacts with the ε-region of pgRNA**

Next, we assessed the interaction of RIG-I with the ε region of HBV pgRNA, that is, εRNA. Pull-down assay showed that Flag-tagged RIG-I was co-precipitated with εRNA but not with ContRNA in HEK293T cells (Figure 4A, top). Similarly, endogenous RIG-I interacted with εRNA albeit weakly (Figure 4A, bottom). We also demonstrated the intracellular co-localization of RIG-I with εRNA in Huh-7.5 cells (Figure 4B). In addition,
RNA-binding protein immunoprecipitation (RIP) assay revealed that the full-length of HBV pgRNA was detected in the RIG-I-immunoprecipitated complex, and Δ5 pgRNA as well as Δ3 pgRNA were also detected (Figure S4A), which is seemingly inconsistent with the results by the functional assay (Figures 3C, 3D, 3F and S3C). These results suggest that the ε region is required for its interaction with RIG-I, but only the 5′-ε region is necessary to activate RIG-I pathway. We further tried to determine which region of RIG-I mediates its interaction with HBV pgRNA. Both RIP assay and RNA pull-down assay with several deletion mutants of RIG-I showed that the C-terminal portion of RIG-I (C-RIG) including its helicase domain and repressor domain (RD) except for CARDs can bind to HBV pgRNA (Figures 4C, S4B and S4C). In addition, gel shift assay showed that the interaction of HBV εRNA or pgRNA was impaired with the RD or C-RIG mutant, respectively, each of which carries a point mutation (K888E) that abolishes its RNA-binding activity (Cui et al., 2008) (Figure 4D). A similar result was also obtained by RIP assay, wherein the wild-type C-RIG but not the K888E mutant was co-immunoprecipitated with HBV pgRNA (Figure S4D), like HCV RNA that was previously reported to interact with RIG-I (Figure S4E). We also confirmed the interaction of HBV pgRNA with endogenous RIG-I in HepG2 cells, whereas its interaction with other nucleic acid sensors, such as IFI16 and MDA5 (Yoneyama et al., 2005), was not detected (Figure 4E). These data indicate that the 5′-ε region of viral pgRNA functions as an HBV-associated molecular pattern to be specifically recognized by RIG-I and can trigger IFN-λ response.

**RIG-I exerts an antiviral activity by counteracting the interaction of HBV polymerase with pgRNA**

We next assessed the contribution of RIG-I pathway in antiviral defense against HBV infection. RIG-I knockdown in PHH resulted in a higher HBV genome copy number at 10 days after infection with HBV-C, as compared with PHH treated with control siRNA (Figure 5A). A similar observation was made for RIG-I siRNA-treated HuS-E/2 cells (Figure S5A). These results indicate an implicated role of RIG-I as an innate sensor to activate antiviral response against HBV infection. On the other hand, it has been previously reported that the 5′-ε region of HBV pgRNA is important to serve as a binding site of viral
P protein for initiating reverse transcription (Bartenschlager and Schaller, 1992). As consistent with this, we showed that the P protein interacts with εRNA in Huh-7.5 and HEK293T cells, by fluorescence resonance energy transfer (FRET) analysis (Figure 5B) and RNA pull-down assay (Figure S5B), respectively. These findings facilitated us to examine whether RIG-I could block the access of P protein toward the ε region. As we expected, recombinant RIG-I protein suppressed the interaction of P protein with pgRNA in a dose-dependent manner (Figure 5C). Such an inhibitory effect was also observed in Huh-7.5 cells by expression of wild-type RIG-I as well as its T55I (Sumpter et al., 2005; Saito et al., 2007) or K270A (Takahasi et al., 2008) mutant (Figures 5D and S5C), both of which are not able to induce ligand-dependent activation of the downstream signaling but retain their RNA-binding activities. On the other hand, the K888E (Cui et al., 2008) mutant could not inhibit the binding of P protein with pgRNA (Figures 5D and S5C). In addition, treatment with recombinant IFN-λ1 in Huh-7.5 cells upregulated the amount of the mutant RIG-I protein (T55I) (Figure S5D), resulting in a partial inhibition of the P protein interaction with pgRNA, and this inhibitory effect was abrogated by RIG-I knockdown (Figure 5E). In fact, FRET analysis showed that the P protein-εRNA interaction was significantly suppressed by expression of the RIG-I RD (WT) alone but not the mutant RD (K888E) (Figure S5E). Furthermore, HBV replication was also suppressed by expression of the RIG-I RD (WT) in Huh-7.5 cells, wherein any IFN induction is not observed, while the mutant RD (K888E) did not affect viral replication (Figure 5F). These findings revealed another aspect of RIG-I as a direct antiviral factor through its interference with the binding of HBV P protein to pgRNA in an IFN pathway-independent manner.

The εRNA restricts HBV replication in human hepatocyte-chimeric mice
Lastly, based on the above results, we tried to harness the therapeutic potential of the P protein-interacting εRNA for the control of HBV infection. A vector was designed to include a 63-bp DNA oligo, which is transcribed into an εRNA. We confirmed in the in vitro experiments using Huh-7.5 cells that εRNA induced by this vector-driven expression is capable to function as a decoy RNA to interfere with the binding of HBV P protein to pgRNA and to inhibit viral replication in an IFN-independent manner (Figures 6A, and 6B,
left). On the other hand, εRNA did not show any difference in HCV replication as compared with control (Figure 6B, right). In order to evaluate the therapeutic efficacy of εRNA in vivo, we exploited HBV infection model of human hepatocyte-chimeric mice. HBV-infected mice underwent intravenous administration with the εRNA expression vector loaded in a liposomal carrier, a multifunctional envelope-type nanodevice (MEND) for efficient delivery, for 2 weeks. Treatment with εRNA-MEND significantly suppressed the elevation of the number of viral genome copies in the sera by less than one tenth of those for control mice (Figure 6C). Consistently, immunofluorescence analyses showed that the expression of HBV core antigen (HBcAg) in the liver tissues of εRNA-MEND-treated chimeric mice was remarkably reduced as compared with those of control mice (Figure 6D).

DISCUSSION

The innate immune system acts as a front line of host defense against viral infection. In this step, PRRs play a crucial role in the recognition of invading viruses. In particular, nucleic acid sensing of viruses is central to the initiation of antiviral immune responses. In this study, we tried to seek for a relevant nucleic acid sensor(s) for HBV and to characterize the IFN response during HBV infection. As a result, we have identified RIG-I as an important innate sensor of HBV to predominantly induce type III IFNs in hepatocytes through its recognition of the 5’-ε stem-loop of HBV pgRNA (Figures 1-4). In this respect, there have also been several reports showing that HBV X or P protein interacts with MAVS or competes for DDX3 binding with TBK1, respectively (Wei et al., 2010; Wang and Ryu, 2010; Yu et al., 2010), and inhibits RIG-I-mediated type I IFN pathway, which possibly enables HBV to evade from antiviral innate immune response. This would mirror the important role of RIG-I-mediated signaling for antiviral defense against HBV infection, although further investigation will be required to determine whether other sensing molecules except for RIG-I are engaged in the activation of innate responses in other cell types including dendritic cell subsets. Interestingly, Lu et al. have recently showed that the genotype D of HBV is sensed by MDA5 but not RIG-I, which is based only upon the
analyses with HBV genome (2-fold) plasmid transfection in a single cell line Huh-7 (Lu et al., 2013). In this respect, we presume that such seemingly contradictory results may arise mainly from the difference in HBV genotype: It has been reported that the genotype D is phylogenetically different from the genotypes A, B and C, which we analyzed in this study (Kato et al., 2002).

In addition, according to our results (Figure 1C and S1C), HBV-induced type III IFN response does not seem to be efficient as compared with the case with NDV infection. We speculate that the weakness of the IFN response during HBV infection may attribute at least in part to these viral evasions from host-cell control, which would be supported by our preliminary data showing that one HBV mutant, which generates viral RNAs including pgRNA but lacks the ability to express whole viral proteins including HBV X and P proteins, can induce higher amounts of IFN-λ1 than intact HBV (Figure S6). In relevance with this, our present data indicate that the interaction of HBV P protein with the 5'-ε stem-loop affects the RIG-I-mediated recognition of viral pgRNA and the subsequent downstream signaling events, which may likely suppress the induction of IFN-λs. This may provide a novel aspect of HBV P protein in terms of viral evasion from RIG-I activation. As for the mechanism for the preferential induction of type III IFNs in hepatocytes in response to HBV as well as HCV (Nakagawa et al., 2013; Park et al., 2012), we may speculate the existence of a hepatocyte-specific factor(s) which is selectively involved in type III IFN gene induction, although this issue merits further investigation including epigenetic evaluation of human hepatocytes. We also found that either of the 5'- or 3'-ε region of pgRNA could interact with RIG-I but it was only the 5'-ε region that contributed to the induction of IFN-λ1 (Figures 3D and S4A). In this respect, we presume that some co-factor(s) may additionally determine the preferential use of the 5'-ε region for RIG-I activation, however, it would be a next interesting issue to be solved. In addition to this, our data demonstrated a hitherto-unidentified function of RIG-I as a direct antiviral factor against HBV infection (Figure 5). Mechanistically, RIG-I was found to counteract the accessibility of HBV P protein to the 5'-ε stem-loop of pgRNA, which is an important process for the initiation of viral replication (Bartenschlager and Schaller, 1992). As is the case with this, several viral PAMPs known to be recognized by RIG-I, for example, the
poly-U/UC tract in the 3’ non-translated region of HCV genome (Saito et al., 2008) and 5’ terminal region of influenza virus genome (Baum et al., 2010) were previously reported to be directly or indirectly critical for viral replication (You and Rice, 2008; Huang et al., 2005; Moeller et al., 2012). In this respect, one could envisage that such an exquisite targeting by RIG-I would confer a unique machinery to ensure efficient antiviral activities of RIG-I. Therefore, RIG-I is likely to play dual roles as an innate sensor and as a direct antiviral effector for host defense during viral infection.

In relation to the evaluation of the experiments shown in Figure 6C and 6D, we additionally analyzed the following points: When we treated HepG2 cells with εRNA-MEND or Control-MEND, in both cases we hardly detected the massive induction of cytokines such as TNFa, IL6 and CXCL10 (data not shown). This was further confirmed by analyzing SCID mice injected with εRNA-MEND or Control-MEND (data not shown). In addition, εRNA-MEND has the specific effect on the replication of HBV but not HCV in Huh-7.5 cells (Figure 6B). These data suggest that the results (Figures 6C and 6D) may not be mainly influenced by massive production of antiviral cytokines, although the cross-reactivity of cytokines should be still carefully considered. Therefore, it is presumed that the effect of εRNA may be based on not only its antagonistic activity but also its cytokine-inducing activity. These findings may afford a new therapeutic modality in replace of conventional antiviral drugs that have been reported to have a risk to develop drug-resistance HBV (Song et al., 2012). The present study may provide a better approach to the strategy for development of nucleic acid medicine, and offer an attractive clinical option for the therapy against not only HBV but also possibly other virus infections.

**EXPERIMENTAL PROCEDURES**

**Infection of human hepatocyte-chimeric mice with HBV and in vivo treatment with εRNA**

To generate human hepatocyte-chimeric mice, uPA^+/+^/SCID mice, were transplanted with commercially available cryopreserved human hepatocytes (a 2-year-old Hispanic female; BD Bioscience) as described previously (Tateno et al., 2004). Chimeric mice were intravenously infected with HBV-C (10^6 copies per mouse) derived from patient with
chronic hepatitis (Sugiyama et al., 2006). Total RNAs were isolated from liver tissues at 0, 4 or 5 weeks after infection, and subjected to quantitative RT-PCR (qRT-PCR). In preparation for εRNA treatment, HBV infection at 3 weeks after infection was confirmed by measuring the number of viral genome copies in the sera of HBV-infected chimeric mice by qPCR analysis, and at 4-week postinfection, εRNA expression vector or empty vector loaded in a liposomal carrier, a multifunctional envelope-type nanodevice (MEND), was administered intravenously at a dose of 0.5 mg/kg of body weight (n = 3 per group) every two days for 14 days. Serum samples were subjected to qPCR for the quantification of DNA copy numbers of HBV as described previously (Nakagawa et al., 2013).

**HBV infection in human hepatocytes and quantification of encapsidated HBV DNA**

HBV infection in PHH or HepG2-hNTCP-C4 cells was performed at 10 or 100 genome equivalents per cell, respectively, in the presence of 4% PEG8000 at 37 °C for 24 hr as previously described (Sugiyama et al., 2006; Watashi et al., 2013; Iwamoto et al., 2014). Lamivudine (50 µM; Sigma) was added in Huh-7 culture media during HBV production. HBV DNA was purified from intracellular core particles as described previously (Turelli et al., 2004; Fujiwara et al., 2005). Briefly, cells were suspended in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA and 1% NP-40. Nuclei were pelleted by centrifugation at 4 °C and 15,000 rpm for 5 min. The supernatant was adjusted to 6 mM MgOAc and treated with DNase I (200 µg/ml) and of RNase A (100 µg/ml) for 3 hr at 37 °C. The reaction was stopped by addition of 10 mM EDTA and the mixture was incubated for 15 min at 65 °C. After treatment with proteinase K (200 µg/ml), 1% SDS and 100 mM NaCl for 2 hr at 37 °C, viral nucleic acids were isolated by phenol:chloroform:isoamyl alcohol (25:24:1) extraction and ethanol precipitation with 20 µg glycogen. Copy numbers of HBV DNA were measured by qPCR with the indicated primers (Table S3).

**qRT-PCR analysis**

Total RNAs were isolated from culture cells or frozen liver tissue using Isogen (Nippon Gene) and were treated with DNase I (Invitrogen). cDNA was prepared from total RNAs using ReverTra Ace (TOYOBO). qRT-PCR was performed using SYBR Premix Ex Taq
(TAKARA) and analyzed on a StepOnePlus real-time PCR system (Applied Biosystems). Detailed information about the primers used here is shown in Table S3. Data were normalized to the expression of \textit{GAPDH} or HBV RNAs for each sample.

**RIP assay**

After 2-h incubation with the antibody as indicated for immunoprecipitation, cell lysates were mixed with Protein-G Dynabeads (Invitrogen) and further incubated for 1 h with gentle shaking. After washing three times, the precipitated RNAs were analysed by qRT-PCR with appropriate primers to detect the target RNA. The amount of immunoprecipitated RNAs is represented as the percentile of the amount of input RNA (%input). The detail was described in the Supplemental Experimental Procedures.

**Supplemental Information**

Document S1. Figures S1–S5, Tables S1–S4, and Supplemental Experimental Procedures

Document S2. Article plus Supplemental Information

**AUTHOR CONTRIBUTIONS**

S.S., K.L., T.K. and T.H. carried out most of the experiments and analyzed data. Y.T. provided materials of HBV and designed the protocol for infection. Y.I. conducted HBV infection in chimeric mice and preparation of human hepatocytes, and S.M., T.Watanabe, S.I., S.T. and Y.T. performed the related analysis and contributed to the interpretation of the results. C.M.R. offered critical advice on the whole manuscript and provided a pair of Huh-7 and Huh-7.5 cell lines. K.W. and T.Wakita provided HepG2-hNTCP-C4 cells. T.K. carried out FRET analysis. Y. Sakurai, Y. Sato, H.A. and H.H. syntheses of plasmid-loaded MEND, and M.K. contributed to establishment of the protocols for \textit{in vivo} treatment. A.T. supervised the project, designed experiments and wrote the manuscript with critical input from the coauthors, and all authors contributed to discussing the results.
ACKNOWLEDGMENTS
We thank M. Hijikata and K. Shimotohno for HuS-E/2 cell line, N. Sakamoto for Huh-7.5.1/Rep-Feo-1b cells, J. Miyazaki for pCAGGS vector, A. Miyawaki for pCAGGS-YFP vector, T. Fujita for the luciferase reporter plasmid p-55C1BLuc, A. Takada for VSV, H. Kida for NDV, H. Ishizu and T. Hirose for technical advice on RIP assay, and A. Bergthaler, A. Shlomai, T. Saito and M. Yasuda for critical reading of the manuscript and helpful advice. The authors are grateful for financial supports from the Ministry of Health, Labour and Welfare of Japan (Grant-in-Aid to A.T. and Y.T.), the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid for Scientific Research (A) (25253030) to A.T., Grant-in-Aid for Scientific Research on Innovative Areas (25115502, 23112701) to A.T., Grant-in-Aid for Young Scientists (B) (25870015) to S.S.), IRYO HOJIN SHADAN JIKOKAI (H. Tanaka & N. Takayanagi) to A.T., the Kato Memorial Bioscience Foundation to A.T., the Yasuda Medical Foundation to A.T., the Takeda Science Foundation to A.T., and THE WAKSMAN FOUNDATION OF JAPAN to A.T. Y.I. is an employee of PhoenixBio Co., Ltd.

REFERENCES


inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun. 443, 808-813


Figure 1. IFN-λ induction in human hepatocytes in response to HBV infection

(A) Quantitative RT-PCR (qRT-PCR) analysis of IFNL1 (left), IFNA4 (middle) and IFNB1 (right) mRNA at the indicated times after transfection with 1.24-fold the HBV genome (genotype Ae, Bj or C) or empty vector (Mock) in HepG2 cells. (B) ELISA of IFN-λ1 at 48 or 72 hr after transfection with the HBV genome in HepG2 cells. The dot line indicates the minimum detectable amount (31.2 pg/ml) of IFN-λ1 by the ELISA kit. ND, not detected, indicates below the minimum detectable amount. (C) qRT-PCR analysis of IFNL1, IFNL2, and IFNL3 mRNA at 24 hr after infection with HBV, NDV (multiplicity of infection=10) or mock (-), or media-treated Lamivudine (LAM) as control in primary human hepatocytes (PHH). The mRNA copy number (± SD) of each subtype of type III IFN per 1 µg total RNA upon HBV-C infection is as follows: IFNL1 (83,197.6 ± 6,241.4) and IFNL2/3 (409,280.6 ± 119,676.2). (D) Time course analyses by qRT-PCR of IFNL1, OAS2, RSAD2, IFNB1 mRNA and pgRNA at the indicated times after HBV infection in HepG2-hNTCP-C4 cells. The effect of Lamivudine treatment was also analyzed. (E) qRT-PCR analysis of IFNL1, IFNL2, IFNL3, IFNA4, IFNB1, CXCL10, OAS2 and RSAD2 mRNA of liver tissues at 4 or 5 weeks after infection with HBV-C in chimeric mice. (-), uninfected mice. Red lines represent the mean of each dataset. *P < 0.05 and **P < 0.01 vs control. RE, relative expression. (A–D) Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. See also Figure S1.

Figure 2. RIG-I-dependent IFN-λ induction in response to HBV infection

(A) HepG2 cells treated with control siRNA (Control) or siRNA targeting RIG-I, IFI16 or cGAS were transfected with the HBV-C genome for 48 or 72 hr. The amount of IFN-λ1 were measured by ELISA. The dot line indicates the minimum cytokine expression detected (31.2 pg/ml) of IFN-λ1 by the ELISA kit. ND, not detected, indicates below detectable concentrations (left), and knockdown efficiency was analyzed by immunoblotting (IB) (right). (B) qRT-PCR analysis of IFNL1 mRNA in Huh-7 or Huh-7.5 cells transfected with the HBV-Ae genome (at 24 h after transfection) or stimulated with 3pRNA (1 µg/ml) for 6 hr. (C) HepG2 cells treated with control siRNA (Control) or the indicated siRNAs were transfected with the HBV-C genome. At 48 hr after transfection,
total RNAs were subjected to qRT-PCR analysis for IFNL1. (D) qRT-PCR analysis of IFNL1 mRNA in siRNA-treated PHH at 24 hr postinfection with indicated HBV genotype. Mock, empty vector-transfected. (-), uninfected. Data were normalized to the expression of GAPDH. Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. *P < 0.05 and **P < 0.01 vs control in (B) or HBV-infected control group in (A, C and D). NS, not significant. See also Figure S2.

**Figure 3. RIG-I activation is mediated by its recognition of the 5’-ε region of HBV pgRNA**

(A) Luciferase activity of an IFN-λ1 reporter plasmid after 24 hr of stimulation with nucleic acids (2 µg/ml) extracted from Huh-7 cells transfected with control plasmid (Mock) or the HBV-Ae genome with or without RNase A or DNase I treatment. RLU, relative luciferase units. (B) Huh-7 cells treated with control or HBV RNA-targeted siRNA were transfected with the HBV-Ae genome or mock. After 24 hr of transfection, total RNAs were subjected to qRT-PCR for IFNL1. (C and D) A schematic representation of four types of HBV RNAs, pgRNA (3.5-kb), 2.4-kb, 2.1-kb and 0.7-kb RNAs in (C), and two deleted forms of pgRNA, Δ5 and Δ3, in (D). The overlapping region is shown in blue. qRT-PCR analysis of IFNL1 mRNA of HEK293T cells after 24 hr of transfection with the indicated expression vectors. Data were normalized to the amount of each HBV RNA expression (C and D). (E) A schematic representation of pgRNA, εRNA or control RNA (ContRNA) (left). HEK293T cells treated with control or RIG-I siRNA were unstimulated (Mock) or stimulated with εRNA for 12 hr. Total RNAs were subjected to qRT-PCR for IFNL1 (middle). qRT-PCR analysis of IFNL1 mRNA in HEK293T cells after 12 hr of stimulation with εRNA or ContRNA (right). Each of the RNAs was prepared by in vitro transcription. (F) HEK293T cells were transfected with each plasmid for stem-loop mutants of pgRNA (5STM, 3STM or 5&3STM), and then subjected to qRT-PCR analysis as described in (C). *P < 0.05 and **P < 0.01 vs control in (A, B and E) or vs 3.5K in (C, D and F). NS, not significant. See also Figure S3.

**Figure 4. RIG-I interacts with the ε region of pgRNA**
(A) RNA pull-down assay showing the binding activity of the indicated RNAs to Flag-tagged RIG-I (Flag-RIG-I) in HEK293T cells (top) or endogenous RIG-I in HepG2 cells (bottom). (B) FRET analysis for the interaction of YFP-tagged RIG-I (YFP-RIG-I) with rhodamine (ROX)-conjugated εRNA (εRNA-ROX) or ContRNA (ContRNA-ROX). Representative fluorescence images of YFP, ROX and FRET^C/YFP (the ratio of corrected FRET (FRET^C) to YFP). Arrowheads indicate area showing high FRET efficiency. Bar: 20 µm. Right, Dot plot of FRET^C/YFP ratio (small horizontal bars, mean). (C) RIP assay with HEK293T cell lysates expressing several Flag-tagged deletion mutants of RIG-I and pgRNA expression vector by using anti-Flag antibody. Immunoprecipitated pgRNA was quantitated by qRT-PCR and normalized to the amount of immunoprecipitated proteins (Figure S4C) and is represented as fraction of input RNA prior to immunoprecipitation (%input). (D) Gel-shift analysis of complex formation between εRNA and recombinant RIG-I RD (WT) or RD (K888E). Arrowheads denote position of unbound RNA and RNA–RIG-I complexes. (E) RIP assay with HepG2 cell lysates prepared after 48 hr of transfection of the HBV-C genome by using anti-RIG-I, anti-IFI16, anti-MDA5 or control IgG. The immunoprecipitated pgRNA was measured by qRT-PCR (top) as described in (C). Whole cell expression and immunoprecipitated amounts of RIG-I, IFI16 and MDA5 (bottom). Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. *P < 0.05 and **P < 0.01 vs control in (B and E). NS, not significant. See also Figure S4.

Figure 5. RIG-I functions as an antiviral factor by counteracting the interaction of HBV P protein with pgRNA

(A) qPCR analysis of copy numbers of encapsidated HBV DNA (left) and qRT-PCR analysis of RIG-I (middle) and IFNLI mRNA (right) in control or RIG-I siRNA-treated PHH after 10 days of infection with HBV-C. (B) FRET analysis for the interaction between YFP-tagged P protein (YFP-P) or YFP and εRNA-ROX as described in Figure 4B. Bar: 20 µm. Arrowheads indicate area showing high FRET efficiency. (C) HEK293T cell lysates expressing pgRNA and HA-tagged P protein (HA-P) were incubated with the indicated amount of recombinant RIG-I (rRIG-I). The interaction of pgRNA with HA-P was analyzed
by RIP assay and qRT-PCR analysis as described in Figure 4C. (D) Cell lysates from Huh-7.5 cells expressing HBV pgRNA, HA-P, and Flag-RIG-I or its mutants as indicated were subjected to RIP assay for the characterization of the capability of RIG-I to counteract the interaction of pgRNA with HA-P, as described in Figure 4C. (E) The effect of rIFN-λ1 treatment on the interaction of pgRNA with HA-P in Huh-7.5 cells was assessed by RIP assay. Huh-7.5 cells expressing both pgRNA and HA-P were treated with rIFN-λ1 (100 ng/ml) for 24 hr, and subjected to RIP assay as described in Figure 4C. RIG-I dependency was also determined by RIG-I knockdown analysis. (F) Huh-7.5 cells were transfected with an expression vector for RIG-I RD (WT) or RD (K888E), together with the HBV-Ae genome. After 72 hr of transfection, copy numbers of encapsidated HBV DNA were measured (left), as described in (A). Expression of Flag-RIG-I RD (WT) and RD (K888E) (right). *P < 0.05 and **P < 0.01 vs control. NS, not significant. See also Figure S5.

Figure 6. Inhibition of HBV replication by εRNA

(A) Huh-7.5 cells were transfected with expression vectors for HA-P and εRNA, together with the HBV-Ae genome. RIP assay was performed to evaluate the effect of εRNA on the interaction between HA-P and pgRNA, as described in Figure 5D. (B) Copy numbers of encapsidated HBV DNA in Huh-7.5 cells expressing the HBV-Ae genome and εRNA, as determined by qPCR (left). HCV replication in Huh-7.5.1/Rep-Feo-1b cells expressing εRNA, as determined by luciferase assay (right). (C) HBV-infected mice were intravenously administrated with the εRNA expression vector (εRNA-MEND) or empty vector (Control-MEND) loaded in liposomal carrier at a dose of 0.5 mg/kg of body weight every two days for 14 days. Serum HBV DNA in HBV-infected chimeric mice was determined by qPCR (n = 3 per group). Day 0 indicates the time of the initiation of administration. (D) Immunofluorescence imaging was performed for the detection of HBcAg (red) and human albumin (green) in the liver sections of HBV-infected chimeric mice at 14 days after treatment with εRNA-MEND or Control-MEND as described in Methods. Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. **P < 0.01 vs control. NS, not significant.
Figure 5 Sato et al.

A

PHH

Copy number (x 10^9)

siRNA:

PHH

Infection:

HBV-C

RIG-I mRNA (RE)

RIG-I mRNA (RE)

 siRNA: Control RIG-I

Infection: HBV-C

PHH

IFN1 mRNA (RE)

PHH

siRNA: Control RIG-I

Infection: HBV-C

B

YFP-P

εRNA-ROX

FRET εYFP

Huh-7.5

Transfection: YFP

FRET εYFP

High

Low

C

HEK293T

pgRNA

% input

rRIG-I: 0 0 1 10 (µg)

HA-P: + + +

RIP: IgG α-HA

D

Huh-7.5

pgRNA

% input

HA-P: - + + +

Flag-RIG-I: - - WT T55I K270A K888E

RIP: α-HA

E

Huh-7.5

pgRNA

% input

HA-P: - + + +

rIFN-λ1: - - + +

siControl: + + + +

RIP: α-HA

F

Huh-7.5

Copy number (x 10^9)

Transfection: HBV-Ae

Control RD(WT) RD(K888E)

Transfection: HBV-Ae

IB: α-Flag

IB: α-β-actin
Figure 6 Sato et al.

A. Huh-7.5 pgRNA

<table>
<thead>
<tr>
<th>HBV-Ae</th>
<th>+</th>
<th>+</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>HA-P</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>εRNA</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>RIP</td>
<td>α-HA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

%input

B. Huh-7.5

Vector: Control εRNA

Copy number (x 10^4)

Transfection: HBV-Ae

Relative luciferase units

C. In vivo experiments

In vivo experiments

Copy number

Time after treatment (days)

D. HBcAg Human albumin Merged

εRNA-MEND

Control-MEND